Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03859869 · ClinicalTrials.gov registry record · Phase 4
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
A Phase 4 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03859869 is a Phase 4 study that was terminated before completion, run by AbbVie. The registered enrollment target is 1 participants.
The verdict
NCT03859869, a Phase 4 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.
Interventions
- DRUG Placebo
- DRUG Pancrelipase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2022-03-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03859869
The ClinicalTrials.gov registry entry for NCT03859869 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03859869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03859869 about?
NCT03859869 is a clinical study titled "A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)". This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.
What is the current status of trial NCT03859869?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2020-02-25. Estimated completion is 2022-03-23.
What interventions are being tested in trial NCT03859869?
The interventions under investigation include: Placebo (DRUG), Pancrelipase (DRUG).
Who is sponsoring clinical trial NCT03859869?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.